Moderna is a Hold as mNEXSPIKE gains traction and the pipeline advances, but shrinking revenue, heavy losses, and negative free cash flow keep the story high risk.
Moderna (MRNA) is a Hold for moderate-risk investors with a medium-term horizon. The investment case rests on a strong mRNA platform, a cash position that supports continued research, and a pipeline with several late-stage programs. The problem is timing: 2025 revenue fell to $1.94B from $3.20B in 2024, 2025 net loss reached $2.82B, and free cash flow was negative $2.06B.
The commercial business has one clear bright spot. mNEXSPIKE captured approximately 24% of the U.S. retail COVID vaccine market during its first 2025-2026 season and approximately 34% among adults aged 65 and older. Moderna also reiterated 2026 revenue growth of up to 10%, supported by mNEXSPIKE and long-term partnerships in the UK, Canada, and Australia.
The stock price of $56.02 sits above the analyst consensus target of $50.84, while the consensus breakdown shows 1 Buy, 17 Holds, and 3 Sells. Moderna has meaningful upside if flu approval, oncology data, and rare-disease milestones convert into commercial products. Until those events become operating results, the stock deserves a disciplined Hold rather than a premium growth multiple.
Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna is a biotechnology company focused on messenger RNA medicines. The company employs approximately 4,700 people and trades on Nasdaq under the ticker MRNA. Its portfolio spans infectious disease vaccines, oncology therapeutics, and rare-disease treatments.
Moderna's 2026 10-K identifies three commercial products: Spikevax and mNEXSPIKE for COVID-19, and mRESVIA for RSV. The 2025 business generated revenue entirely through Product Sales in the segment view, while the annual income statement recorded $1.94B of revenue. That revenue base remains concentrated in respiratory vaccines, leaving the company exposed to vaccination rates, strain selection, reimbursement, and competitive market share.
The strategic objective is to use cash from vaccines to fund a broader mRNA medicines business. The 10-K lists 35 therapeutic and vaccine programs, including six in late-stage development. This structure gives Moderna more shots on goal than a single-product biotechnology company, but it also requires substantial investment before pipeline assets can produce revenue.
Moderna operates through one commercial economic engine: Product Sales. The three marketed products all sit within respiratory vaccines, with COVID products providing the established commercial base and mRESVIA extending the portfolio into RSV. The pipeline adds seasonal flu, combination vaccines, norovirus, oncology, and rare disease.
The respiratory franchise is entering a diversification phase. mRNA-1010 is under review in the United States, Europe, Canada, and Australia after a unanimous recommendation from the U.S. VRBPAC. mCOMBRIAX is approved in the European Union and under review in Canada, Australia, and Japan. mRNA-1403 remains in Phase III after its interim analysis failed to meet the statistical criteria for early success.
The non-vaccine pipeline has greater long-term economic value but also higher clinical risk. Intismeran autogene is being developed with Merck across nine Phase II and Phase III studies. The propionic acidemia program is fully enrolled in its registrational study, with data expected in 2026. These programs are important because they could reduce Moderna's dependence on seasonal vaccine revenue.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
mNEXSPIKE is Moderna's flagship commercial growth product. During its first 2025-2026 season, it captured approximately 24% of the total U.S. retail COVID vaccine market and approximately 34% of the market among adults aged 65 and older. That age group is commercially important because older adults face higher hospitalization risk and represent a core vaccination population.
The product's real-world evidence adds support to its launch performance. Adjusted vaccine effectiveness against hospitalization was approximately 59% among adults aged 65 and older and approximately 67% among adults aged 75 and older during the 2025-2026 season. The analysis was not designed as a head-to-head comparison with a competitor, but the numerical results were higher than those observed for a competitor vaccine in separately matched analysis.
mNEXSPIKE also targets the XFG strain selected by U.S. and European health authorities for the 2026-2027 season. The product is approved in the United States, Europe, Canada, Australia, Japan, and Taiwan. Its one-fifth mRNA dose relative to Spikevax, combined with the Phase III head-to-head result showing non-inferior efficacy and a 13.5% relative vaccine efficacy advantage in adults aged 65 and older, gives Moderna a credible product-level argument.
Moderna's competitive advantage is built on the combination of mRNA sequence design, lipid nanoparticle delivery, and manufacturing expertise. The 10-K describes chemically modified uridine, proprietary untranslated-region sequences, cell-targeting elements, and lipid formulations designed to improve protein expression, tolerability, and repeat dosing.
The platform has produced commercial proof rather than remaining a laboratory concept. Moderna moved from founding in 2010 to three commercial products and a 35-program pipeline. That history lowers some technical risk for related programs because the company can reuse manufacturing processes, delivery knowledge, and clinical experience across modalities.
Intismeran illustrates the platform's higher-value application. Moderna reported five-year Phase II data in combination with KEYTRUDA in adjuvant melanoma, while ASCO data demonstrated de novo neoantigen-specific T cells. Management also reported that approximately 29% of neoantigens placed into treatment cassettes are immunogenic and that artificial intelligence is being used to improve the selection algorithm.
The moat is not permanent. Pfizer, BioNTech, GSK, Novavax, Sanofi, large pharmaceutical companies, academic institutions, and government-backed groups all compete across parts of Moderna's markets. The platform earns a premium only when it delivers better products, faster development, or commercially meaningful medicines.
Moderna has spent several years reshaping its manufacturing network around a smaller number of strategic sites. The 10-K describes a global network that includes Moderna-built and managed facilities in the UK, Canada, and Australia, as well as U.S. manufacturing and packaging capabilities. A Marlborough, Massachusetts facility began clinical batch supply for Intismeran in September 2025.
The Q2 2026 results show operating efficiency improving at the margin. Cost of sales fell 22% year over year to $93M, R&D declined 7% to $651M, and SG&A fell 6% to $216M. Management attributed the cost-of-sales improvement to lower unused manufacturing capacity costs and the R&D reduction to the wind-down of several late-stage programs.
For 2026, management lowered its cost-of-sales projection by $100M to $1.70B and its R&D projection by $100M to $2.90B. SG&A remains approximately $1.00B. Excluding a $900M litigation charge, the company expects GAAP operating expenses of $4.70B and cash costs of approximately $4.00B. Capital expenditures are projected at $200M to $300M.
The operating model remains difficult because seasonal vaccine sales arrive unevenly while research costs continue throughout the year. Q2 revenue was $145M, but Q3 is expected to represent approximately 55% of second-half revenue. That phasing increases the importance of manufacturing discipline and inventory planning.
Moderna's most relevant market is respiratory vaccines. The company's historical framing places the respiratory opportunity at approximately $30B annually, including roughly $15B for COVID-19, $10B for RSV, and $6B for flu. Moderna also previously projected respiratory product sales of $8B to $15B in 2027 under different vaccination-rate, efficacy, and market-share outcomes.
That market is large but seasonal and politically sensitive. COVID vaccination rates have normalized from pandemic levels, while annual strain updates create recurring development and manufacturing demands. Moderna's 2026 guidance explicitly factors in possible future declines in COVID vaccination rates and assumes no revenue from mFLUSIVA or mCOMBRIAX.
The broader biotechnology market expands Moderna's strategic opportunity beyond vaccines. Published industry estimates place the global biotechnology market between approximately $546B and $2.42T for 2025-2026, depending on the definition used. More relevant to Moderna, red biotechnology was estimated at $669.8B in 2026 and $997.7B by 2030. These figures describe a large field, not guaranteed revenue for MRNA.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Moderna serves several distinct customer groups. U.S. retail pharmacies and healthcare providers purchase or administer respiratory vaccines, while governments and public-health systems create demand through procurement, recommendations, and reimbursement. During Q2, revenue was 60% U.S. and 40% international. For the first half of 2026, the mix was 31% U.S. and 69% international.
Long-term strategic partnerships drove the international contribution. Moderna signed a joint procurement contract with the European Commission for up to 24 million doses of mRESVIA across six countries. The company also expanded local manufacturing and supply arrangements in Brazil, the UK, Canada, and Australia.
The end users are concentrated in older adults, high-risk adults, and patients with serious diseases. mRESVIA is approved for adults aged 60 and older and certain high-risk adults aged 18 to 59. mNEXSPIKE's strongest early uptake came from adults aged 65 and older, where it captured approximately 34% of the U.S. retail market.
Oncology and rare disease customers will be different from vaccine customers. These products require specialist prescribing, payer coverage, hospital adoption, and evidence of durable clinical benefit. The Merck partnership for Intismeran and the Recordati collaboration for propionic acidemia give Moderna commercial partners for two important pipeline areas.
Pfizer and BioNTech are Moderna's primary COVID vaccine rivals, with BioNTech also using mRNA technology. GSK is a major RSV competitor and entered the U.S. market before Moderna. Novavax and Sanofi compete in COVID and seasonal vaccine categories, while Pfizer also competes in RSV and offers an antiviral treatment that can reduce reliance on vaccination.
Moderna's advantage versus traditional vaccine companies is platform breadth and mRNA specialization. Its disadvantage is commercial scale. GSK, Sanofi, Pfizer, and other established players bring mature distribution systems, broad portfolios, and long-standing relationships with healthcare providers and governments.
The oncology landscape is even more competitive. Moderna's Intismeran program competes with established checkpoint inhibitors, personalized cancer vaccine programs, cell therapies, gene therapies, and other immuno-oncology approaches. The Merck collaboration provides validation and a commercial partner, but Phase III efficacy and regulatory approval remain essential before the program can justify a major change in Moderna's earnings profile.
Moderna's mNEXSPIKE launch demonstrates that the company can take share from established products when it presents a differentiated clinical profile. The 24% overall U.S. retail share and 34% share among adults aged 65 and older are concrete evidence of competitive traction. The next test is whether that traction offsets broader COVID market contraction.
Public-health policy directly affects Moderna's revenue. U.S. and European health authorities selected the XFG strain for the 2026-2027 COVID season, and Moderna is updating Spikevax and mNEXSPIKE to target it. The company also reported that mRNA-1010 received a unanimous VRBPAC recommendation ahead of its August 5 PDUFA date.
Government procurement is both a commercial channel and a geopolitical tool. The European Commission contract for up to 24 million mRESVIA doses, Brazil's local manufacturing agreement, and Moderna's expanded CEPI partnership for an Ebola vaccine connect the company to public-health preparedness and regional supply security.
Seasonality is the most immediate operating force. Management described Q2 as light for seasonal vaccines, reported revenue of $145M, and expects Q3 to account for approximately 55% of second-half revenue. This uneven revenue pattern makes quarterly losses less informative than annual cash consumption, but it also leaves the stock sensitive to each vaccination season.
The international footprint reduces reliance on a single government market but increases exposure to regulatory differences, procurement cycles, and local manufacturing execution. Moderna's facilities and partnerships in the UK, Canada, Australia, Brazil, and Europe give it broader access while adding operational complexity.
Cash and marketable securities remain strong enough to fund research, but 2025 free cash flow was negative $2.06B, underscoring how quickly the balance sheet is being used to support the pipeline.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue dropped from $3.20B in 2024 to $1.94B in 2025 while the net loss reached $2.82B, showing that the income statement is still under heavy pressure.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management reiterated up to 10% 2026 revenue growth, with mNEXSPIKE and partnerships in the UK, Canada, and Australia doing the heavy lifting.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The shares at $56.02 trade above the analyst consensus target of $50.84, and the report argues Moderna does not yet deserve a premium growth multiple.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Consensus is cautious at 1 Buy, 17 Holds, and 3 Sells, while the report’s fair value sits at $50 and the recommendation remains Hold.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Moderna remains one of the clearest pure-play ways to gain exposure to mRNA medicine. Its platform has produced three commercial products, mNEXSPIKE has taken meaningful U.S. retail share, and the company has built a pipeline across vaccines, oncology, and rare disease. Those facts justify keeping the long-term story alive.
The financial evidence demands restraint. Revenue has fallen sharply from the pandemic peak, operating losses remain large, free cash flow is negative, and analyst estimates do not reach positive average EPS until 2029. The balance sheet buys time, but time is valuable only if clinical programs and commercial launches convert it into durable cash flow.
At $56.02, MRNA is priced as a recovery story rather than a distressed biotechnology asset. A Hold is the balanced position: the platform and pipeline deserve recognition, while the earnings statement and analyst consensus argue against chasing the stock above the $50.00 fair value estimate.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Moderna’s latest drop looks more like regulatory panic than a broken thesis. With an Aug. 5 FDA decision now in sight and the flu program still under active review, the selloff looks overdone.
Moderna’s latest surge looks earned, not speculative. Science Day gave the market a concrete post-COVID roadmap, and the August 5 flu decision gives MRNA a real catalyst investors can actually underwrite.
Moderna is a transition story with real mRNA platform strength, but weak earnings and heavy COVID dependence keep it in Hold territory. The stock’s appeal hinges on late-stage pipeline catalysts and a cash runway that supports the pivot.